Home » Stocks » Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. (VRCA)

Stock Price: $7.89 USD -0.21 (-2.59%)
Updated Oct 27, 2020 12:38 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 203.68M
Revenue (ttm) n/a
Net Income (ttm) -32.96M
Shares Out 25.81M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $7.89
Previous Close $8.10
Change ($) -0.21
Change (%) -2.59%
Day's Open 8.13
Day's Range 7.89 - 8.32
Day's Volume 20,783
52-Week Range 6.02 - 18.67

More Stats

Market Cap 203.68M
Enterprise Value 158.90M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.81M
Float 12.62M
EPS (basic) -1.31
EPS (diluted) -1.32
FCF / Share -1.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.55M
Short Ratio 17.06
Short % of Float 20.22%
Beta 2.30
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.58
Revenue n/a
Operating Income -33.04M
Net Income -32.96M
Free Cash Flow -33.44M
Net Cash 44.78M
Net Cash / Share 1.73
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -24.52%
ROE -52.60%
ROIC -57.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$19.00*
(140.81% upside)
Low
15.0
Current: $7.89
High
25.0
Target: 19.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-30.08-21.88-4.46-1.91
Net Income-28.21-20.65-4.46-1.91
Shares Outstanding24.9014.662.856.32
Earnings Per Share-1.13-1.41-1.56-0.30
Operating Cash Flow-27.41-17.87-4.58-1.61
Capital Expenditures-0.68-0.77--
Free Cash Flow-28.09-18.65-4.58-1.61
Cash & Equivalents62.0290.318.660.53
Total Debt0.19---
Net Cash / Debt61.8390.318.660.53
Assets68.4291.919.080.54
Liabilities3.412.480.620.42
Book Value65.0289.43-7.04-2.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Verrica Pharmaceuticals Inc.
Country United States
Employees 17
CEO Ted White

Stock Information

Ticker Symbol VRCA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VRCA
IPO Date June 15, 2018

Description

Verrica Pharmaceuticals, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.